Syntegon is expanding its pharmaceutical processing and packaging business with the acquisition of Azbil Telstar, to date part of the Japanese Azbil Corporation, which is listed on the Tokyo Stock Exchange Prime Market. Telstar, headquartered in Terrassa (Barcelona), Spain, is a manufacturer and supplier of equipment for the global life and health science industries. With a workforce of approx. 900 employees, production plants in Spain, China, and the UK, as well as engineering, sales, and service offices all over the world, Telstar is a significant addition to Syntegon’s portfolio for liquid pharmaceutical processing. Further growth opportunities will also arise for Telstar as part of the Syntegon Group. Syntegon and Azbil have signed an agreement to not disclose any financial details. The transaction is subject to regulatory approval.
Seamless solutions from a single source
Telstar has a strong experienced team serving pharma, life sciences, and medtech customers around the world, especially in Southern and Western Europe, the U.S., and India. Freeze-dryers as well as loading and unloading systems including comprehensive services are the most important portfolio enhancements for Syntegon and ideally complement its leading vial filling and isolator solutions. Freeze-drying, also known as lyophilization, is a common process step to ensure the long-term stability of drugs, such as antibiotics, vaccines, or biologics. Telstar's business will benefit from its integration into the Syntegon Group with its complete solutions for pharmaceutical processing and packaging technology.
With the expanded portfolio, Syntegon will be in an even better position to offer both pharmaceutical manufacturers and CMOs seamless line solutions from a single source. Moreover, the Syntegon service network will be expanded significantly by the Telstar service engineers, adding geographical coverage, proximity, and application expertise.
https://www.syntegon.com/press/set-for-further-growth-syntegon-announces-acquisition-of-telstar
